Navigation Links
Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
Date:3/30/2009

ST. LOUIS and MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement to supply high quality services and oligonucleotides to Gene Oracle, an innovative gene synthesis company. Under the terms of the agreement, Sigma-Aldrich will be the exclusive supplier of custom oligonucleotides for Gene Oracle, and the two Companies will engage in co-marketing efforts to promote the GeneIOS system and their expert gene synthesis services (http://www.sigma.com/oligos).

The GeneIOS system is unique in the market because it enables researchers to design and create synthetic genes quickly, accurately and at a lower cost than traditional gene synthesis service companies.

"Our partnership with Gene Oracle is focused on providing researchers with an optimal solution for their gene synthesis needs. Sigma-Aldrich has earned the research community's trust with our consistently high quality DNA oligonucleotides that we believe are an ideal complement to Gene Oracle's gene synthesis platform," said Khalil Arar, business development director for Sigma-Aldrich Custom Products. "We are proud to be the exclusive supplier of oligonucleotides to Gene Oracle, and we look forward to building awareness of our joint services through co-marketing efforts."

"Gene Oracle is focused on expanding the use and role of GeneIOS in the gene synthesis market," said Ken Mitchell, chief financial officer of Gene Oracle, "and with Sigma-Aldrich's global reach, plus their high quality oligonucleotides, the relationship is expected to provide Gene Oracle with not only strong marketing support but also high quality building blocks for our GeneIOS synthesis solution."

Sigma-Aldrich's oligonucleotides are an integral component of the Gene Oracle gene synthesis platform. After customers design an optimized gene sequence using the GeneIOS software, incorporating desired protein expression and other factors such as protein binding sites, Sigma-Aldrich can generate high quality oligonucleotides that can be easily assembled to create synthetic genes within a single day. Sigma-Aldrich guarantees the quality of its oligonucleotides, making them an ideal component of the GeneIOS solution.

Sigma-Aldrich offers a comprehensive collection of customized oligonucleotide services, from DNA oligos and probes to RNA and siRNA oligos and peptide library synthesis. For more information on Sigma-Aldrich custom oligonucleotides, or to order, please visit http://www.sigma.com/oligos.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About Gene Oracle: Founded in 2004, Gene Oracle Inc. is a privately held Mountain View, California-based corporation focused on developing and commercializing innovative products and services for the life science research market. Gene Oracle manufactures custom synthetic genes, and provides molecular biology consulting services to pharmaceutical, biotechnology, and academic research institutions. More information about GeneIOS is available at the Company's website at https://www.geneoracle.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):